Skip to main content

Table 2 ADP-induced platelet aggregation in four subjects treated with clopidogrel with and without PPI co-therapy

From: Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?

Medication Subjects    
  #1 (wt/wt) #2 (wt/wt) #3 (wt/*2) #4 (wt/*2)
baseline normal normal normal normal
(day 0) 85 U 79 U 89 U 101 U
clopidogrel mono-therapy inhibited inhibited normal inhibited
(day 7) 42 U 16 U 97 U 31 U
clopidogrel and omeprazole inhibited inhibited n.s.* normal
taken together (day 14) 44 U 10 U   74 U
clopidogrel and omeprazole n.s.* n.s.* n.s* normal
intake separated (day 21)     67 U
clopidogrel and rabeprazole n.s.* n.s.* n.s.* inhibited
taken together (day 28)     43 U
  1. The reference range of the test was 53-122 U.
  2. Clopidogrel intake inhibits ADP-induced platelet aggregation in subjects showing the expected clopidogrel effect. Normal platelet function under clopidogrel mono-therapy represents a non-responder status. The normalization of platelet function by co-therapy with clopidogrel and PPI after platelet function is inhibited by clopidogrel mono-therapy indicates a pharmacologically relevant drug interaction.
  3. *n.s., not studied, according to protocol.